- Home
- ECPG vs MIRM Comparison
ECPG vs MIRM Comparison
Compare ECPG & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECPG
- MIRM
- Stock Information
- Founded
- ECPG 1998
- MIRM 2018
- Country
- ECPG United States
- MIRM United States
- Employees
- ECPG N/A
- MIRM N/A
- Industry
- ECPG Finance Companies
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- ECPG Finance
- MIRM Health Care
- Exchange
- ECPG Nasdaq
- MIRM Nasdaq
- Market Cap
- ECPG 806.1M
- MIRM 2.5B
- IPO Year
- ECPG 1999
- MIRM 2019
- Fundamental
- Price
- ECPG $40.17
- MIRM $50.47
- Analyst Decision
- ECPG Strong Buy
- MIRM Strong Buy
- Analyst Count
- ECPG 3
- MIRM 9
- Target Price
- ECPG $62.67
- MIRM $66.22
- AVG Volume (30 Days)
- ECPG 262.9K
- MIRM 449.6K
- Earning Date
- ECPG 08-06-2025
- MIRM 08-06-2025
- Dividend Yield
- ECPG N/A
- MIRM N/A
- EPS Growth
- ECPG N/A
- MIRM N/A
- EPS
- ECPG N/A
- MIRM N/A
- Revenue
- ECPG $1,380,750,000.00
- MIRM $379,251,000.00
- Revenue This Year
- ECPG $21.70
- MIRM $35.83
- Revenue Next Year
- ECPG $8.86
- MIRM $16.83
- P/E Ratio
- ECPG N/A
- MIRM N/A
- Revenue Growth
- ECPG 11.49
- MIRM 69.31
- 52 Week Low
- ECPG $26.45
- MIRM $34.47
- 52 Week High
- ECPG $51.77
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- ECPG 56.60
- MIRM 59.77
- Support Level
- ECPG $38.37
- MIRM $47.89
- Resistance Level
- ECPG $39.86
- MIRM $51.93
- Average True Range (ATR)
- ECPG 1.05
- MIRM 1.45
- MACD
- ECPG 0.13
- MIRM -0.23
- Stochastic Oscillator
- ECPG 66.95
- MIRM 63.86
About ECPG Encore Capital Group Inc
Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumers repay their obligations and work toward financial recovery. Encore has only a reportable segment portfolio purchasing and recovery.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.